UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-A

 

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

Evaxion Biotech A/S

(Exact Name of Registrant as Specified in its Charter)

 

 

 

The Kingdom of Denmark N/A
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
   
Bredgade 34E    
1260 Copenhagen K    
Denmark N/A
(Address of principal executive offices) (Zip code)

 

Securities to be registered pursuant to Section 12(b) of the Act:
 
Title of each class
to be so registered 		  Name of exchange on which
each class is to be registered
American Depositary Shares, each representing 1 Ordinary Share   The Nasdaq Stock Market LLC
Ordinary Shares, DKK 1 nominal value per share* The Nasdaq Stock Market LLC*
           

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. The American Depositary Shares represent the right to receive the Ordinary Shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from registration under Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.
     

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 

333-251982

 

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 

 

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

The description of the securities of Evaxion Biotech A/S (the “Registrant”) being registered is set forth under “Description of Share Capital” and “Description of American Depositary Shares” in the Registrant’s registration statement on Form F-1 (File No. 333-251982), originally filed with the Securities and Exchange Commission (the “Commission”) on January 8, 2021, as amended, including any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which description and prospectus are incorporated herein by reference.

 

Item 2. Exhibits.

 

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

2 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Evaxion Biotech A/S
   
Date:     January 26, 2021 By: /s/ Lars Staal Wegner, MD
    Name: Lars Staal Wegner, MD
    Title: Chief Executive Officer
     

3